Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pasireotide LAR followed by Pasireotide LAR+ Everolimus · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Functional tumors, pre-treated | EXPERIMENTAL | - |
| Functional tumors, treatment naïve | EXPERIMENTAL | - |
| Nonfunctional tumors, pretreated 1 | EXPERIMENTAL | - |
| Nonfunctional tumors, pretreated 2 | EXPERIMENTAL | - |
| Nonfunctional tumors, treatment-naïve 1 | EXPERIMENTAL | - |
| Nonfunctional tumors, treatment-naïve 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pasireotide LAR followed by Pasireotide LAR + Everolimus | DRUG | - |
| Everolimus followed by Pasireotide LAR + Everolimus | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of grade 1/2 advanced pulmonary or gastroenteropancreatic neuroendocrine tumor * Progressive disease within last 12 months (only patients with nonfunctional tumors) * Documented liver metastasis * Measurable disease per RECIST determined by multiphase MRI o...
Pasireotide LAR followed by Pasireotide LAR + Everolimus is an investigational sequential treatment regimen being studied in gastroenteropancreatic neuroendocrine tumors of the pulmonary or gastroenteropancreatic system. It combines pasireotide LAR, a long-acting somatostatin analogue, with everolimus. The regimen is developed by Novartis AG (ticker: NVS) and has been evaluated in a Phase 1 clinical trial.
Pasireotide, the backbone of this regimen, targets somatostatin receptors SSTR2, SSTR3, SSTR1, and SSTR5 as an agonist. By binding these receptors, it acts as a somatostatin analogue. Everolimus, the combination partner, is an mTOR inhibitor. Together, the regimen is designed to target neuroendocrine tumor cells through these distinct pathways.
Novartis AG, which trades under the ticker NVS, is developing Pasireotide LAR followed by Pasireotide LAR + Everolimus. Novartis is the sponsor of the clinical trial evaluating this sequential regimen in patients with advanced neuroendocrine tumors.
Pasireotide LAR followed by Pasireotide LAR + Everolimus is in Phase 1 clinical development. It is an investigational regimen and has not been approved by the FDA for any indication. The Phase 1 trial has been completed.
Pasireotide LAR followed by Pasireotide LAR + Everolimus has been studied in one clinical trial: NCT01263353, titled "Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs." This completed Phase 1 trial enrolled 36 patients in Germany and was randomized and controlled.